We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+15.65%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16M
AUM Growth
+$3.05M
(+24%)
Cap. Flow
+$1.62M
Cap. Flow
% of AUM
10.11%
Top 10 Holdings %
Top 10 Hldgs %
98.74%
Holding
12
New
4
Increased
2
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$1.81M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$934K |
| 3 |
Zoetis
ZTS
|
+$805K |
| 4 |
Biogen
BIIB
|
+$770K |
| 5 |
DexCom
DXCM
|
+$223K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Align Technology
ALGN
|
+$1.4M |
| 2 |
Eli Lilly
LLY
|
+$1.08M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$339K |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$309K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Edwards Lifesciences
EW
$50B
| $4.17M | 26.11% |
103,833
+48,000
| +86% | +$1.81M |
|
|
2
Acadia Pharmaceuticals
ACAD
$4.55B
| $2.31M | 14.47% |
72,723
-10,000
| -12% | -$339K |
|
|
PETX
3
DELISTED
Aratana Therapeutics, Inc.
PETX
| $2.04M | 12.79% |
218,515
| – | – |
|
4
Johnson & Johnson
JNJ
$617B
| $1.54M | 9.61% |
13,000
| – | – |
|
|
5
DexCom
DXCM
$28.8B
| $1.25M | 7.79% |
56,800
+10,000
| +21% | +$223K |
|
|
6
Eli Lilly
LLY
$1.03T
| $1.07M | 6.68% |
13,310
-13,500
| -50% | -$1.08M |
|
|
TSRO
7
DELISTED
TESARO, Inc.
TSRO
| $1M | 6.27% |
+10,000
| New | +$934K |
|
|
8
Zoetis
ZTS
$31.9B
| $827K | 5.17% |
+15,900
| New | +$805K |
|
|
9
Biogen
BIIB
$30.7B
| $814K | 5.09% |
+2,600
| New | +$770K |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $760K | 4.75% |
6,199
-2,400
| -28% | -$309K |
|
11
Regeneron Pharmaceuticals
REGN
$77.4B
| $201K | 1.26% |
+500
| New | +$201K |
|
|
12
Align Technology
ALGN
$12.4B
| – | – |
-17,319
| Closed | -$1.4M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, March Altus Capital Management held 12 positions worth $16M, up 24% from $12.9M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
March Altus Capital Management deployed $1.62M of net new capital in Q3 2016, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was TESARO, Inc.: 10,000 shares worth $1M.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier.
On the sell side, the largest reduction was Eli Lilly, an estimated $1.08M trimmed.
- March Altus Capital Management's largest Q3 2016 buy was TESARO, Inc.: 10,000 shares worth $1M.
- March Altus Capital Management added most to Edwards Lifesciences in Q3 2016, an estimated $1.81M increase.
- March Altus Capital Management's biggest Q3 2016 reduction was Eli Lilly, cutting an estimated $1.08M.
- March Altus Capital Management fully exited Align Technology in Q3 2016, selling an estimated $1.4M.
- March Altus Capital Management's ten largest holdings make up 99% of its $16M portfolio in Q3 2016.
- March Altus Capital Management opened 4 new positions and closed 1 in Q3 2016.
- March Altus Capital Management's portfolio value rose 24% quarter-over-quarter to $16M.
Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.